Galera Therapeutics, Inc. (GRTXD)
| Market Cap | 16.25M +731.3% |
| Revenue (ttm) | n/a |
| Net Income | 63.52M |
| EPS | 128.97 |
| Shares Out | 1.04M |
| PE Ratio | 0.12 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,447 |
| Open | 16.00 |
| Previous Close | n/a |
| Day's Range | 16.00 - 19.00 |
| 52-Week Range | 3.02 - 30.00 |
| Beta | 2.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Galera Therapeutics
As of August 3, 2026, Galera Therapeutics, Inc. was acquired by Obsidian Therapeutics, Inc., in a reverse merger transaction. Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company’s lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets... [Read more]
Financial Performance
Financial StatementsNews
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineer...
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
CAMBRIDGE, Mass. and MALVERN, Pa., April 14, 2026 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibi...
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
CAMBRIDGE, Mass. & MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical...
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agr...
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.
Galera Announces Board Approval of Complete Liquidation and Dissolution
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary...
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics ...
Galera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the p...
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 202...
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential stra...
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps
Galera shares tank after US FDA declines to approve inflammation disease drug
Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammation in patients with advanced head and neck cancer undergoing st...
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...
Galera Expands Commercial Leadership Team
Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients NDA based on two positive randomized, double-blinded, placebo-controlled trials w...
Galera to Present at Piper Sandler Annual Healthcare Conference
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...